Agios targets H2 2026 proof-of-mechanism readout for oral PKU drug AG-181
The Phase 1 trial testing whether AG-181 lowers phenylalanine in PKU patients runs a 2028 completion date, raising the question of what data a mid-trial readout can actually support.
Executive Summary
- Agios has guided to a proof-of-mechanism data readout for its oral PKU candidate in the back half of 2026, well ahead of the trial's own multi-year completion timeline.
- The study is designed around safety and pharmacokinetics first, with phenylalanine reduction tracked as a secondary measure, so any interim signal will be read as pharmacodynamic evidence rather than a clinical efficacy result.
- No other program in active PKU development shares this drug's stabilizer mechanism, placing it apart from the enzyme substitution, cofactor, and gene-therapy approaches that dominate the field.
- The trial has progressed normally since initiation, with recruitment underway on schedule and no protocol instability to date.
The guidance
Agios told investors at the J.P. Morgan Healthcare Conference in January 2026 that it expects to confirm proof of mechanism from the Phase 1b AG-181 trial in PKU during the second half of the year. The trial in question, NCT07241234, is a Phase 1 study testing AG-181 in adults with phenylketonuria (PKU), a genetic disorder in which the body cannot break down the amino acid phenylalanine. The study is not registrational and targets an anticipated enrollment of 20 patients. Agios+1Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease ...Jan 12, 2026A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With PhenylketonuriaNCT07241234
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial actually measures
The registered primary endpoint is the number of subjects with adverse events and serious adverse events, by type, severity, and relationship to the study drug, a safety and tolerability measure rather than an efficacy endpoint. Phenylalanine reduction from baseline appears among seven secondary endpoints alongside pharmacokinetic measures such as maximum concentration and area under the concentration-time curve. Any H2 2026 data disclosure would draw on this secondary pharmacodynamic measure well ahead of the trial's own primary completion date of January 17, 2028. NCT07241234A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With PhenylketonuriaNCT07241234
Trial status
The trial moved from Not yet recruiting to Recruiting on April 24, 2026, and enrolled patients at two sites in the United States and Poland under an unchanged 20-patient anticipated enrollment target. That enrollment figure has not moved since the study was first posted in November 2025, and the trial has logged no protocol amendments to its endpoints, eligibility criteria, or completion date. The study requires patients with a documented PAH gene mutation including the R408W variant and a plasma phenylalanine concentration above 600 micromoles per liter, a population selected to show a measurable phenylalanine response if the mechanism holds. NCT07241234A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With PhenylketonuriaNCT07241234
The competitive field
Phenylketonuria treatment today rests on enzyme substitution with pegvaliase, cofactor therapy with sapropterin, and an emerging cohort of newer mechanisms in testing, including PTC Therapeutics' sepiapterin in Phase 3, Otsuka's JNT-517 in Phase 3, and Sanofi and NGGT's gene-therapy programs in Phase 1 and Phase 2, none of which share AG-181's phenylalanine hydroxylase stabilizer mechanism. AG-181 sits without a direct mechanism-matched comparator in this indication, making its pharmacodynamic result the first test of this specific stabilizer approach in PKU rather than a comparison against an established class benchmark.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.